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ABSTRACT 
Objective: Chronic diseases like COPD have significant effects on patient’s health-related quality of life (HRQoL). HRQoL measures additional 
indices as compared to objective measurements like spirometry. Our aim is to assess and compare the disease-specific quality of life in Chronic 
Obstructive Pulmonary Disease patients using St. George’s Respiratory Questionnaire (SGRQ-C) receiving Salmeterol/Fluticasone (SF), 
Formoterol/Budesonide (FB), Formoterol/Fluticasone (FF).  
Methods: A prospective, open-label, randomized, parallel group study conducted at a tertiary care teaching hospital in South India. A 6-months 
follow-up of 90 patients with severe and very severe COPD randomized to receive Salmeterol/Fluticasone, Formoterol/Budesonide, and 
Formoterol/Fluticasone in appropriate doses according to their global initiative for chronic obstructive lung disease (GOLD) severity. After 
spirometry, St. George’s Respiratory Questionnaire (SGRQ-C) was administered at baseline and after 180 d to assess improvement in lung function 
and HRQoL. Statistical analysis used: Data analyzed using SPSS version: 13.0. General linear repeated measures using the post-hoc Bonferroni 
method assessed significance between treatment groups.  
Results: Significant decrease (P<0.05) in each SGRQ-C domains and total scores as well as improvement in FEV1 (P<0.05) was observed in all study 
subjects. The mean SGRQ-C total score for the group I subjects (SF) at the initial visit was 86.69 and the scores reduced to 58.78 at final visit (i.e. 
after using SF for 6 mo). This reduction was highly significant statistically (t=10.989, p=0.000) at 95% CI. The mean SGRQ-C total scores for group II 
subjects (FB) at initial visit were 85.85 and the scores reduced to 67.98 at the final visit. This reduction was highly significant statistically (t=9.669, 
p=0.000) at 95% CI. The mean SGRQ-C total scores for group III subjects (FF) at initial visit were 83.96 and the scores reduced to 70.37 at final visit 
(after 6 mo). This reduction was highly significant statistically (t=12.285, p=0.000) at 95% CI. 
Conclusion: Maximum improvement in HRQoL (P<0.05) was noted in patients receiving Salmeterol/Fluticasone with respect to SGRQ-C (activity, 
impact and total) scores and FEV1. This improvement with SF was due to its greater effect in patients with severe and very severe chronic 
obstructive pulmonary disease. There was a significant improvement in QoL with SF as compared to FB and FF in severe and very severe COPD 
patients. Subsequently, the three combined inhaled corticosteroids and bronchodilators showed similar improvements in lung functions and Health 
related quality of life throughout the study. 
Keywords: Chronic obstructive pulmonary disease, Bronchodilators, Health-related quality of life, Inhaled corticosteroids, St. George’s respiratory 
questionnaire. 
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INTRODUCTION 
Health-related quality of life (HRQoL) assessment in COPD is a 
more responsive outcome measure than spirometry. HRQoL 
measurement facilitates the evaluation of the efficacy of medical 
interventions and also detection of groups at risk for psychological 
or behavioral problems [1]. QoL unique to each individual is 
influenced by the perception of disease. COPD is one among the 
common chronic diseases, which has significant effects on 
patient’s health and QoL. The prevalence of COPD has been 
increasing since the early 1980s for all age, sex, and racial groups 
[2]. Despite better understanding of the disease process and 
improved treatment modalities, the increasing incidence and 
prevalence of COPD in many parts of the world continue to make it 
a global health concern [3]. 
The basic pathology behind COPD is characterized by poorly 
reversible airflow obstruction and an abnormal inflammatory 
response in the lungs. Hence, the main goal of treatment is to improve 
the airflow and reduce the inflammation. Current clinical (GOLD) 
guidelines recommend the use of combined inhaled corticosteroids 
and bronchodilators as the mainstay of therapy in COPD [4, 5]. 
The goals in using combined inhaled corticosteroids and bronchodilators 
in COPD treatment can be viewed in two ways. First to gain control over 
the underlying disease process and secondly to maintain this control for 
as long as possible with least amount of side effects [6].  
Relatively little is known about the impact of COPD on health-
related quality of life, even with the existing epidemiological and 
economic literature on COPD. Health-related quality of life is 
increasingly being used in the evaluation of medical 
interventions on chronic diseases. The clinical measures provide 
valuable information only about the affected organ system but 
not the functional impairment (physical, emotional and social) 
which is also important to the patients in their everyday lives. 
Thus it is important that treatment goals should not only be 
directed towards improving physiologic end points but also 
patient’s physical and mental health (i.e. quality of life) with the 
overall goal of reducing the debilitating impact of COPD on 
patient’s lives [7, 8]. 
Salmeterol/Fluticasone (SF), Formoterol/Budesonide (FB), Formoterol/ 
Fluticasone (FF) are the three different combinations of inhaled 
corticosteroids and bronchodilators used commonly in severe and 
very severe COPD patients.  
Disease-specific health status measures are distinguished by its 
higher responsiveness than the generic measures and are widely 
used in clinical trials. St. George’s Respiratory Questionnaire (SGRQ) 
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was designed to measure HRQoL both in asthma and COPD patients, 
but no studies measuring the improvement in HRQoL in COPD 
patients using the SGRQ-C comparing three different combined 
inhaled corticosteroids and bronchodilators is reported [9]. 
This study was conducted to assess and compare quality of life in 
patients with COPD receiving Salmeterol/Fluticasone (SF), 
Formoterol/Budesonide (FB), and Formoterol/Fluticasone (FF) at 
six months duration so as to assist in making an informed decision 
when choosing one of the three different combined inhaled 
corticosteroids and bronchodilators. 
MATERIALS AND METHODS 
Study design 
The study was conducted at Princess Esra Hospital, a tertiary care 
teaching hospital in Hyderabad, South India, during the period 
September 2013 to February 2014. The patients enrolled into the 
study were COPD patients taken from the Departments of 
Pulmonology and Medicine. It was a prospective open-labeled 
randomized study of 6 mo duration in which 90 severe 
(30≤FEV1<50% predicted) and very severe (FEV1<30% 
predicted) COPD patients (OP/IP) who are prescribed with any 
one of the following combinations (SF/FB/FF) were selected. In 
our study, we have divided 90 COPD patients into 3 groups (Group 
I, Group II & Group III) each group consisting of 30 patients. Group 
I was prescribed with medication SF (Salmeterol/Fluticasone), 
Group II with medication FB (Formoterol/Budesonide) and Group 
III with medication FF (Formoterol/Fluticasone). We used two 
different parameters such as St. George’s Respiratory 
Questionnaire (SGRQ-C) and Spirometry test (mean FEV1 initial & 
final visit) to assess and compare the health-related quality of life 
(HRQoL) in COPD patients.  
The three therapeutic alternatives considered were:  
 Salmeterol/Fluticasone (SF): use of combined salmeterol/ 
fluticasone 25/250 μg bid in GOLD stages III and IV patients in 
addition to the standard therapy already in use.  
 Formoterol/Budesonide (FB): use of combined formoterol/ 
budesonide 6/200 μg bid in GOLD stages III and IV patients. 
 Formoterol/Fluticasone (FF): use of combined formoterol/ 
fluticasone 6/250 μg bid in GOLD stages III and IV patients.  
Patients who were able to perform study-related tests after signing the 
consent form were included in the study. Those who were already using 
inhaled or oral steroids, having an acute exacerbation of COPD or with 
any other co-morbidities (Tuberculosis, Asthma, Cardiac complications), 
pregnant or lactating woman, pediatric patients and those less than 85% 
adherent to medication were excluded from the study. Medication 
adherence checking was done by the accepted methods like a patient 
interview, medication checking, and prescription refill and health 
outcome measures. Patients satisfying inclusion criteria after giving 
informed consent were randomized by simple randomization method. 
Institutional review board ethics approval for the study protocol was 
obtained from Deccan College of Medical Sciences, Princess Esra 
Hospital, Hyderabad. 
Health-related quality of life (HRQoL) questionnaire 
Enrolled patients received either Salmeterol/Fluticasone (SF), 
Formoterol/Budesonide (FB), Formoterol/Fluticasone (FF). A 
validated version of St. George’s Respiratory Questionnaire (SGRQ-
C) was administered. SGRQ-C is a disease specific questionnaire used 
to measure health-related quality of life in respiratory diseases like 
asthma and COPD. It contains 40 items, categorized in 3 domains 
like symptoms, impacts, and activity. The total score of all these 
domains gives the overall quality of life estimate of each patient. The 
threshold for a clinically significant difference between groups of 
patients and for changes within groups of patients is four units. 
Decrease in the total score reflects improved QoL [10,11]. 
Spirometry was performed before and after bronchodilation to 
assess the baseline status and to confirm the diagnosis of COPD. 
Patients were educated on the use of inhaled medicines. Clinical 
evaluation, SGRQ and spirometry was done during initial (day 1) and 
follow-up visits (after 180 d).  
 
Table 1: Patient demographic characteristics at baseline 
Demography SF FB FF Total (%), (±SD) 
No. of patients enrolled 30 30 30 90 
Study completers  30 30 30 90 
Gender  
Male 22 21 19 62 
Female 8 9 11 28 
Duration in y*(mean±SD) 3.76±2.77 3.12±2.06 2.95±1.89 3.27±2.24 
Age**(mean±SD) 60.5±9.41 62.5±9.69 63.1±10.6 62.0±9.90 
Educational status* 
Illiterate  12 8 10 30 
≤5th Std 10 15 12 37 
6th to 10th 5 6 6 17 
Intermediate 3 1 2 6 
Family history* 
Positive  8 9 6 23 
Negative 26 18 23 67 
Smoking history* 
Current Smoker  10 10 15 35 
Non Smoker 8 9 11 28 
Past Smoker 7 11 9 27 
Lung function** 
FEV1 33.47±7.12 33.73±7.37 33.20±7.72 33.46±7.40 
Quality of life SGRQ-C domains (mean±SD)** 
Symptom 81.32±7.74 81.95±6.21 81.63±5.61 81.63±6.52 
Activity 85.04±10.4 84.71±10.1 81.26±9.43 83.67±9.99 
Impact 89.53±6.67 87.87±6.81 86.37±7.70 87.91±7.06 
Total 86.69±5.39 85.85±5.01 83.96±5.51 85.50±5.30 
SF: Salmeterol/Fluticasone, FB: Formoterol/Budesonide, FF: Formoterol/Fluticasone, FEV1: Forced expiratory volume in 1s, SD: Standard deviation, 
SGRQ-C: St. George’s Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease patients, *p value>0.05 not significant by (‘t’ test), **p 
value>0.05 not significant by analysis of variance 
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Statistical analysis 
Data were analyzed by using Statistical Program for Social Science 
(SPSS) version: 13.0. ANOVA was used to test significance within the 
groups at different time intervals. For testing significance between 
groups, students‘t’ test was used.  
Descriptive statistics for improvement in QoL scores and lung 
functions are presented as mean and 95% confidence interval (CI). 
To assess the similarities between the groups at baseline, ANOVA 
(Analysis of Variance) was used. General linear repeated measures 
using post-hoc Bonferroni method assessed significance between 
treatment groups during the study. The significant improvements in 
treatment groups were assessed by one-way ANOVA using post hoc-
Bonferroni that compared means of SGRQ-C scores and lung 
functions during individual follow-ups. 
RESULTS  
Study population 
A total of 90 patients randomized for an equal distribution of 30 
patients in each group i.e. Group-I (Salmeterol/Fluticasone), Group-
II (Formoterol/Budesonide) and Group-III (Formoterol/ 
Fluticasone). The mean age of Group-I, II, III patients who 
participated in the study was 60.5 y (±9.41), 62.5 y (±9.69) and 
63.13 y (±10.61). Out of 90 patients enrolled to the study, 69% were 
males and 31% were females and most of them were illiterate 
(33.33%) and current smokers (33.33%). Demographic data, 
spirometry and QoL scores of the three groups were well matched at 
baseline (P ˃ 0.05) as shown in table 1. 
Spirometry (FEV1) 
At baseline there is no significant difference in FEV1 (P ˃ 0.05), but 
at the final visit there is significant improvement in FEV1 (P<0.05) 
for patients who were taking Salmeterol/Fluticasone (SF), 
Formoterol/Budesonide (FB), but not for patients who were 
taking Formoterol/Fluticasone (FF). The average FEV1 for group I, 
group II and group III subjects at the initial visit was 33.47%, 
33.73% & 33.20% and was increased to 36.60%, 35.8% and 33.4 
as shown in table 2 and fig. 1. A 3% increment in FEV1 was 
reported for the group I subjects (SF) and was highly significant 
statistically (t=-8.833, p=0.000) at 95% CI. For group II subjects 
(FB), a 2% increment in FEV1 was reported and was highly 
significant statistically (t=-9.001, p=0.000) at 95% CI. For group III 




Fig. 1: Mean FEV1 (Initial & final visit) with different treatment 
groups 
 
Quality of Life Improvement (SGRQ-C) 
A rapid improvement in all the domains of QoL was noted in 
study subjects. All the domains of SGRQ-C were well matched at 
baseline between the three groups. Inter-group comparisons 
revealed a more significant (P<0.05) response to SF compared to 
FB and FF in all the domains of SGRQ-C after 6 mo. The mean 
SGRQ-C symptom score for Group-I, Group-II and Group-III 
subjects at the initial visit was 81.32, 81.95 and 81.63 and the 
scores reduced to 54.76, 61.96 and 56.54 (fig. 2) at final visit i.e. 
after 180 d. The mean SGRQ-C activity score for Group-I, Group-
II and Group-III subjects at the initial visit was 85.04, 84.71 and 
81.26 and the scores reduced to 60.29, 68.41 and 74.21 (fig. 3). 
The mean SGRQ-C impact score for Group-I, Group-II and Group-
III subjects at the initial visit was 89.53, 87.87 and 86.37 and the 
scores reduced to 59.26, 69.80 and 72.88 (fig. 4) at final visit i.e. 
after 180 d. The mean SGRQ-C total score for group I subjects 
(SF) at the initial visit was 86.69 and the scores reduced to 58.78 
at final visit (i.e. after using SF for 6 mo). This reduction was 
highly significant statistically (t=10.989, p=0.000) at 95% CI. The 
mean SGRQ-C total scores for group II subjects (FB) at initial 
visit were 85.85 and the scores reduced to 67.98 at the final 
visit. This reduction was also highly significant statistically 
(t=9.669, p=0.000) at 95% CI. The mean SGRQ-C total scores for 
group III subjects (FF) at initial visit were 83.96 and the scores 
reduced to 70.37 at final visit (after 6 mo). This reduction was 
highly significant statistically (t=12.285, p=0.000) at 95% CI as 
shown in table 2 and fig. 5. 
 
 
Fig. 2: Mean SGRQ-C symptom score (Initial & final visit) with 
different treatment groups 
 
 
Fig. 3: Mean SGRQ-C activity score (Initial & final visit) with 
different treatment groups 
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Fig. 4: Mean SGRQ-C impact score (Initial & final visit) with 
different treatment groups 
 
 
Fig. 5: Mean SGRQ-C total score (Initial & final visit) with 
different treatment groups
Table 2: Mean FEV1, SGRQ-C total score (initial & final visit) with different treatment groups 
Strategy FEV1 SGRQ-C total score 
Initial visit Final visit Initial visit Final visit 
SF 33.47 36.60 86.69 58.78 
FB 33.73 35.80 85.85 67.98 
FF 33.20 33.40 83.96 70.37 
FEV1: Forced expiratory volume in 1s, SGRQ-C: St. George’s Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease patients, SF: 
Salmeterol/Fluticasone, FB: Formoterol/Budesonide, FF: Formoterol/Fluticasone 
 
DISCUSSION 
Combined Inhaled corticosteroids and bronchodilators have been 
the mainstay of therapy in patients with COPD. Hence new 
formulations and dosage forms are being continuously developed. 
Clinical studies have shown that treatment with inhaled steroids 
plus bronchodilators improves not only the symptoms of COPD but 
also the quality of life. The present study was designed as an open-
label, randomized trial to compare the quality of life for patients 
using Salmeterol/Fluticasone, Formoterol/Budesonide, Formoterol/ 
Fluticasone. 
The study results, representing responses to a disease-specific 
quality of life instrument SGRQ, demonstrate that COPD treatment 
with Salmeterol/Fluticasone has an additional benefit in health-
related quality of life over that of Formoterol/Budesonide, 
Formoterol/Fluticasone. At baseline, the demographics, SGRQ-C 
scores, and FEV1 values showed no significant difference between 
the three treatment groups. The initial greater SGRQ-C scores 
indicated the decreased quality of life in all the patients. The 
improvement in QoL was evaluated within the group as well as 
between the groups. There was a significant decrease in SGRQ 
scores (P<0.05) during the follow-ups in all the treatment groups 
showing improvement in the quality of life. Although the 
improvement was seen in all the treatment groups at 180 d of 
treatment, it was observed that the improvement seen with 
Salmeterol/Fluticasone group was significantly (P<0.05) greater 
than that of Formoterol/Budesonide, Formoterol/Fluticasone 
treatment group. This may be due to the reason that severe to very 
severe COPD patients (GOLD III & GOLD IV) have responded better 
to Salmeterol/Fluticasone when compared to Formoterol/ 
Budesonide, Formoterol/Fluticasone in the 6 mo course of 
treatment.  
There is some evidence that Salmeterol/Fluticasone may be 
superior to other combined inhaled corticosteroids and 
bronchodilators in patients with severe and very severe COPD. A 
recent meta-analysis of clinical trials with Salmeterol/Fluticasone, 
Formoterol/Budesonide, and Formoterol/Fluticasone suggests that 
Salmeterol/Fluticasone may provide equal or greater COPD control 
in patients with severe to very severe COPD. In the present study, 
the patients included varied from severe to very severe COPD (GOLD 
III to GOLD IV) which was more representative of the spectrum of 
COPD severity seen in routine clinical practice[12,13]. The 
improvements seen in QoL were clinically and statistically favorable 
to Salmeterol/Fluticasone after 180 d of follow-up as compared to 
Formoterol/Budesonide and Formoterol/Fluticasone, whereas 
transient difference was noted in the lung functions. On the 
continuation of treatment for six months, there was a maximum 
improvement in the quality of life of patients between the treatment 
groups. This may suggest that there is an advantage of 
Salmeterol/Fluticasone compared to Formoterol/Budesonide and 
Formoterol/Fluticasone on prolonged therapy. This is further 
supported by the studies reviewed by Neil Barnes [14] where the 
author has concluded that the difference between 
Salmeterol/Fluticasone, Formoterol/Budesonide, and Formoterol/ 
Fluticasone in terms of safety and efficacy may be of importance 
only in patients with COPD that is more difficult to control and 
require higher doses of inhaled steroids. 
Pulmonary function test (FEV1) also improved with 
Salmeterol/Fluticasone and Formoterol/Budesonide during the 6 
mo period of treatment. There was a significant improvement in 
lung function (p<0.05) after 180 d of treatment. There was no 
correlation (r = 0.2) between the changes in QoL scores and change 
in FEV1 values. This may be due to the reason that even with the 
small change in FEV1 values, patients felt much better, because of 
which their quality of life improved to a greater extent.  
There are few studies on the improvement in the quality of life in 
COPD patients using combined inhaled corticosteroids and 
bronchodilators and all of them demonstrated significant 
improvement in the quality of life. They have used generic quality of 
life measures like SF-36. To our knowledge, this may be the first 
study in COPD patients using Saint George's Respiratory 
Questionnaire (SGRQ-C) to compare between three different 
combined corticosteroids and bronchodilators [15]. 
There is a good general consensus that combining medications of 
different pharmacological classes represent a much more 
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convenient strategy in COPD, particularly for severe or very severe 
disease. Additional effects have in fact been proven both in 
functional and in clinical terms under these conditions [16]. In 
particular, health status, quality of life, and exacerbations represent 
the most affected outcomes in more severe COPD (basal FEV1<50% 
predicted) when treated with combined long-acting β2-agonists and 
inhaled corticosteroids over time. These data highlighted the 
favorable therapeutic performance of three different combined 
inhaled corticosteroids and bronchodilators [17]. 
CONCLUSION 
In conclusion, our study demonstrated that SGRQ-C is useful 
outcome measures in Chronic Obstructive Pulmonary Disease 
studies and is able to measure dimensions not measured by 
pulmonary function tests that help to identify subtle differences 
between drugs. All the three combined ICS and bronchodilators 
showed improvement in lung functions and QoL scores. The 
maximum improvement in the quality of life was obtained with 
Salmeterol/Fluticasone in severe and very severe COPD patients. 
More studies comparing different disease-specific instruments such 
as HADS and SGRQ are necessary to identify the ideal HRQoL 
measure in Chronic Obstructive Pulmonary Disease. 
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